Search

Your search keyword '"Stadtmauer, E"' showing total 385 results

Search Constraints

Start Over You searched for: Author "Stadtmauer, E" Remove constraint Author: "Stadtmauer, E"
385 results on '"Stadtmauer, E"'

Search Results

1. Contribution of chemotherapy mobilization to disease control in multiple myeloma treated with autologous hematopoietic cell transplantation

2. P07: RESULTS FROM THE CC-220-MM-001 DOSE-EXPANSION PHASE OF IBERDOMIDE PLUS DEXAMETHASONE IN PATIENTS WITH RELAPSED/REFRACTORY MULTIPLE MYELOMA

4. Third consensus on medical treatment of metastatic breast cancer

6. Predictors of long‐term survival outcomes following receipt of autologous stem cell transplantation for patients with diffuse large/high grade B cell lymphoma.

9. Allogeneic hematopoietic cell transplantation for neuroblastoma: the CIBMTR experience

10. International harmonization in performing and reporting minimal residual disease assessment in multiple myeloma trials

11. Iberdomide in combination with dexamethasone and daratumumab or bortezomib in patients with relapsed/Refractory multiple myeloma: first results from the CC-220-MM-001 study

12. Impact of Pretransplantation Renal Dysfunction on Outcomes after Allogeneic Hematopoietic Cell Transplantation.

20. International myeloma working group (IMWG) consensus statement and guidelines regarding the current status of stem cell collection and high-dose therapy for multiple myeloma and the role of plerixafor (AMD 3100)

37. Characterization of autologous T cells engineered to express NY-ESO-1 TCR with multiplexed CRISPR/Cas9 editing (NYCE T Cells)

41. Second consensus on medical treatment of metastatic breast cancer

42. Treatment of PTLD with Rituximab or Chemotherapy

47. PS1375 UPDATED SAFETY AND EFFICACY FROM A PHASE 2 STUDY OF VENETOCLAX PLUS CARFILZOMIB AND DEXAMETHASONE IN PATIENTS WITH RELAPSED/REFRACTORY MULTIPLE MYELOMA

48. Myeloid derived suppressor cells (MDSCS) reduce the manufacturing feasibilty of gene modified T cells.

49. Outcomes of diffuse large/high grade B cell lymphoma patients following receipt of autologous stem transplantation or chimeric antigen receptor‐modified T cells.

50. International myeloma working group recommendations for the diagnosis and management of myeloma-related renal impairment

Catalog

Books, media, physical & digital resources